BFM
IART icon

Boothbay Fund Management’s Integra LifeSciences IART Stock Holding History

Boothbay Fund Management’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,881
Closed -$334K – 2247
2025
Q4 		$334K Buy
+26,881
New +$357K 0.01% 1369
2022
Q4 		– Sell
-4,734
Closed -$241K – 2192
2022
Q3 		$201K Buy
+4,734
New +$243K 0.01% 1846

Other funds holding IART

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Boothbay Fund Management's IART Position: Q1 2026 in Review

Boothbay Fund Management sold out of Integra LifeSciences (IART) in Q1 2026, closing a stake of 26,881 shares — an estimated $334K sold.

Boothbay Fund Management first reported a position in IART in Q3 2022 and held it in 2 quarters. The position peaked at $334K in Q4 2025. 202 funds tracked by Wall St. Rank hold IART as of Q1 2026.

  • Boothbay Fund Management reported no remaining Integra LifeSciences position as of Q1 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 26,881 Integra LifeSciences shares in Q1 2026, an estimated $334K.
  • Boothbay Fund Management first reported a position in Integra LifeSciences in Q3 2022 and held it in 2 quarters.
  • Boothbay Fund Management's Integra LifeSciences position peaked at $334K in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.